期刊
EXPERT OPINION ON DRUG METABOLISM & TOXICOLOGY
卷 4, 期 7, 页码 965-972出版社
TAYLOR & FRANCIS LTD
DOI: 10.1517/17425255.4.7.965
关键词
efavirenz; treatment naive; novel antiretroviral agents
资金
- NIAID NIH HHS [K23 AI066901] Funding Source: Medline
Background: Efavirenz is a potent, safe and tolerable non-nucleoside reverse transcriptase inhibitor (NNRTI) recommended as initial therapy. Recently, several new antiretroviral drugs, including second generation NNRTIs, protease-inhibitors, an integrase-inhibitor and a CCR5 inhibitor, have become or will be shortly available. Objective: This article will review relevant efficacy and safety data of efavirenz compared to these novel agents or certain common alternate drugs currently used as initial therapy in treatment-naive patients. Methods: Published articles and conference presentations pertaining to efavirenz and/or the newer antiretroviral agents were evaluated. Results/conclusions: Efavirenz will continue to be preferred initial therapy for now. if longer-term studies of integrase inhibitors and second-generation NNRTIs confirm initial findings, they will eventually supplant efavirenz as preferred first-line agents.
作者
我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。
推荐
暂无数据